New Atlas2 天
Breast cancer cure rates almost doubled in combo therapy trial
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
2024乳腺癌外科治疗热点问题丨名家领航，年度盘点
进一步回顾2024年复旦大学附属肿瘤医院乳腺癌诊疗情况，截止到11月底，总乳腺癌手术例数9764例，截止到12月底则10690例，70岁以上的患者800余例，1400余例低-中级别导管原位癌。近7000例患者接受了前哨淋巴结活检，其中前哨淋巴结1到2 ...
Phase III trial shows new treatment boosts cure rate for most common form of breast cancer
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...
Too Old to Operate23 天
Margetuximab Does Not Improve pCR Rate in HER2-Positive Early Breast Cancer
The MARGOT/TBCRC052 trial failed to show a significant improvement in pathologic complete response (pCR) rates with margetuximab compared with trastuzumab in patients with early-stage HER2-positive ...
Medpage Today on MSN14 天
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
生物谷6 天
Nature Medicine：Nivolumab联合化疗——乳腺癌患者的新希望还是挑战？
该研究的突破性发现不仅为ER+/HER2−乳腺癌患者提供了全新的治疗选择，还为未来的个体化治疗开辟了新的方向。通过将免疫 ...
Medpage Today on MSN6 天
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after ...
technologynetworks1 天
Treatment Boosts Cure Rate for Most Common Form of Breast Cancer in Trial
Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Medscape5 天
Real-time PCR as a Diagnostic Tool for Bacterial Diseases
In recent years, quantitative real-time PCR tests have been extensively developed in clinical microbiology laboratories for routine diagnosis of infectious diseases, particularly bacterial diseases.